IQ-AI Limited ( (GB:IQAI) ) has shared an announcement.
IQ-AI Limited has announced an operational update highlighting significant advancements in their use of AI for neuro-oncology. The company is set to release an updated version of its FDA-cleared IB Clinic, incorporating AI to enhance diagnostic capabilities, and is progressing with its Phase 1 trial of gallium maltolate for relapsed glioblastoma. These developments position IQ-AI as a leader in AI-driven medical solutions, promising improved patient outcomes and potentially disrupting current treatment protocols.
More about IQ-AI Limited
IQ-AI Limited, a parent company of Imaging Biometrics, LLC, specializes in developing quantitative imaging platforms and therapeutics to improve the accuracy and efficiency of clinical diagnoses and treatments.
YTD Price Performance: 33.57%
Average Trading Volume: 664,568
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £4.15M
See more insights into IQAI stock on TipRanks’ Stock Analysis page.